EyePoint Pharmaceuticals, Inc.

EYPT

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0002013623-26-000008
Filing date: Mar 5, 2026
Earliest execution date: Mar 4, 2026

Summary

Type

Sell

Net shares

-2,438

% of shares

-100.00%

Amount (USD)

$43,571

Insider confidence score

26.3 out of 100

Positive

  • Small sell amount (<$50K)

Negative

  • Large discretionary sell (≥1% of shares)

Stock transactions

Transaction 1

Security

Common Stock

Action

Exercise

Date

2026-03-04

Code

M

Net shares

+2,438.0

Price per Share

$8.26

Amount (USD)

$20,137.88

Acquired/Disposed

Acquired

Shares Owned Before

0.0

Shares Owned After

2,438.0

Transaction 2

Security

Common Stock

Action

Sell

Date

2026-03-04

Code

S

Net shares

-2,438.0

Price per Share

$17.87

Amount (USD)

$43,571.69

Acquired/Disposed

Disposed

Shares Owned Before

2,438.0

Shares Owned After

0.0

Derivative Transactions

Transaction 1

Security

Stock Option (Right to Buy)

Action

Exercise

Date

2026-03-04

Code

M

Net shares

-2,438.0

Acquired/Disposed

Disposed

Shares Owned Before

85,313.0

Shares Owned After

82,875.0

Filing's footnotes

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.22 to $18.45. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.